Загрузка...
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer (NSCLC), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC...
Сохранить в:
| Опубликовано в: : | Cancer Sci |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676111/ https://ncbi.nlm.nih.gov/pubmed/31222843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14113 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|